<DOC>
	<DOCNO>NCT00074997</DOCNO>
	<brief_summary>The purpose study determine safety efficacy administration cell-delivered ribozyme gene transfer product participant chronic ( last long time ) Human Immunodeficiency Virus Type 1 ( HIV-1 ) infection ( life-threatening infection get infect person 's blood sex infect person ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Autologous Cluster Differentiation 34 ( CD34+ ) Hematopoietic Progenitor Cells Transduced With Placebo Anti- Human Immunodeficiency Virus Type 1 ( HIV-1 ) Ribozyme ( OZ1 ) Participants With HIV-1 Infection</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither participant physician know study medication drug name ) , placebo ( inactive substance compare drug test drug real effect clinical trial ) control study investigate safety efficacy administration autologous cluster differentiation 34 ( CD34+ ) cell transduce placebo anti-HIV-ribozyme ( OZ1 ) participants HIV-1 infection . The total study duration 100 week include follow visit : screening , pre-infusion Days 1-7 , Day 8 , Week 1 , 4 , 8 , 12 , 16 , 20 , 24 , 25 , 26 , 27 , 28 , 30 , 32 , 34 , 36 , 38 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 52 , 56 , 60 , 64 , 68 , 72 , 76 , 80 , 84 , 88 , 92 , 96 100 . Before administration CD34+ final cell product , number procedure perform , include injection granulocyte colony-stimulating factor ( G-CSF ) mobilize CD34+ cell , apheresis transduction CD34+ cell either OZ1 placebo . Participants divide two group : one group receive OZ1-containing CD34+ cell , group receive CD34+ cell alone receive single intravenous infusion ( fluid medicine deliver vein way needle ) CD34+ cell transduce either placebo OZ1 gene transfer product . The final cell product contain approximately 2-20 x 10^7 cells/kilogram autologous CD34+ cell suspension transduce either placebo OZ1 gene transfer product . Primary efficacy assess primarily amount HIV ribonucleic acid ( RNA ) ( viral load ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<criteria>An Human Immunodeficiency Virus 1 ( HIV1 ) infection least 6 month document positive HIV serology include confirmation Western Blot Receiving either first second regimen antiretroviral therapy ( ART ) define 3 antiretroviral drug combination A Viral load le 400 copy per milliliter ( copies/ml ) , measure Roche Amplicor HIV1 Monitor assay , 2 consecutive occasion , least 7 day apart within 45 day prior granulocyte colonystimulating factor ( GCSF ) administration second measurement within 14 day prior GCSF Cluster Differentiation 4 ( CD4+ ) cell count must great 300 cell per cubic millimeter ( cells/mm^3 ) Women men ( partner ) agree use medically accept form contraception safe sexual practice Any previous current Acquired Immunodeficiency Syndrome ( AIDS ) define illness Center Disease Control ( CDC ) case definition , include AIDSrelated dementia ( mental decline ) , exception Kaposi 's sarcoma ( purple brown cancerous pimple skin , often associate AIDS ) Clinically significant clinical laboratory result Participants vein unsuitable study relate procedure Current ART include antiretroviral agent exhibit antagonism use together ( example , zidovudine stavudine ) , current previous ART include hydroxyurea Current pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>Anti-HIV-1 Ribozyme</keyword>
	<keyword>OZ1</keyword>
	<keyword>HIV-1 Infections</keyword>
</DOC>